|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
43,700,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Prelude Therapeutics is a clinical-stage oncology company built on a foundation of drug discovery to deliver precision cancer medicines to underserved patients. Co.'s primary candidates are designed to be oral, potent and selective inhibitors of protein arginine methyltransferase 5 (PRMT5). PRT811, Co.'s second clinical candidate, is a PRMT5 inhibitor that it has optimized for high brain exposure. PRT1419, Co.'s third clinical candidate, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1. PRT2527, Co.'s fourth clinical candidate, is designed to be a potent and selective Cyclin-dependent kinase 9 inhibitor.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
1,789,474 |
Total Buy Value |
$0 |
$0 |
$0 |
$10,263,019 |
Total People Bought |
0 |
0 |
0 |
5 |
Total Buy Transactions |
0 |
0 |
0 |
9 |
Total Shares Sold |
0 |
0 |
0 |
13,280 |
Total Sell Value |
$0 |
$0 |
$0 |
$81,274 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Huang Jane |
President, CMO |
|
2024-04-04 |
4 |
D |
$4.74 |
$15,865 |
D/D |
(3,347) |
51,287 |
|
- |
|
Huang Jane |
President, CMO |
|
2024-04-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
54,634 |
|
- |
|
Huang Jane |
President, CMO |
|
2024-01-04 |
4 |
D |
$3.77 |
$14,492 |
D/D |
(3,844) |
45,259 |
|
- |
|
Huang Jane |
President, CMO |
|
2024-01-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
49,103 |
|
- |
|
Huang Jane |
President, CMO |
|
2023-10-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
39,728 |
|
- |
|
Huang Jane |
President, CMO |
|
2023-07-04 |
4 |
D |
$4.65 |
$15,075 |
D/D |
(3,242) |
30,353 |
|
- |
|
Huang Jane |
President, CMO |
|
2023-07-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,375 |
33,595 |
|
- |
|
Vaddi Krishna |
CEO |
|
2023-05-25 |
4 |
B |
$5.31 |
$4,779 |
D/D |
900 |
1,067,275 |
0.01 |
- |
|
Vaddi Krishna |
CEO |
|
2023-05-24 |
4 |
B |
$5.01 |
$5,011 |
D/D |
1,000 |
1,066,375 |
0.01 |
- |
|
Lim Bryant David |
Chief Legal Officer, Corp Sec. |
|
2023-05-24 |
4 |
B |
$5.39 |
$12,936 |
D/D |
2,400 |
2,400 |
0.01 |
- |
|
Vaddi Krishna |
CEO |
|
2023-05-23 |
4 |
B |
$5.63 |
$66,749 |
D/D |
11,856 |
1,065,375 |
0.01 |
- |
|
Chardonnet Laurent |
Chief Financial Officer |
|
2023-05-23 |
4 |
B |
$5.50 |
$27,500 |
D/D |
5,000 |
42,165 |
0.01 |
- |
|
Orbimed Capital Llc |
Director |
|
2023-05-22 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
10,119,756 |
2.25 |
- |
|
Bonita David P |
Director |
|
2023-05-22 |
4 |
B |
$5.75 |
$4,999,999 |
I/I |
869,565 |
10,119,756 |
2.25 |
- |
|
Huang Jane |
President, CMO |
|
2023-04-06 |
4 |
S |
$6.12 |
$81,274 |
D/D |
(13,280) |
24,220 |
|
- |
|
Huang Jane |
President, CMO |
|
2023-04-04 |
4 |
OE |
$0.00 |
$0 |
D/D |
37,500 |
37,500 |
|
- |
|
Vaddi Krishna |
CEO |
|
2022-12-20 |
4 |
B |
$5.13 |
$98,446 |
I/I |
19,188 |
120,665 |
0.01 |
- |
|
Chardonnet Laurent |
Chief Financial Officer |
|
2022-12-08 |
4 |
B |
$4.76 |
$47,600 |
D/D |
10,000 |
35,873 |
0.01 |
- |
|
Chardonnet Laurent |
Chief Financial Officer |
|
2022-06-01 |
4 |
B |
$4.23 |
$42,300 |
D/D |
10,000 |
24,500 |
0.01 |
- |
|
Combs Andrew |
EVP, Head of Chemistry |
|
2022-03-31 |
4 |
OE |
$1.89 |
$68,157 |
D/D |
36,062 |
304,442 |
|
- |
|
Chardonnet Laurent |
Chief Financial Officer |
|
2022-03-21 |
4 |
A |
$7.51 |
$48,815 |
D/D |
6,500 |
14,500 |
|
- |
|
Morosini Deborah |
EVP, Chief of Clinical Affairs |
|
2021-12-15 |
4 |
AS |
$13.00 |
$373,763 |
D/D |
(28,751) |
444 |
|
- |
|
Morosini Deborah |
EVP, Chief of Clinical Affairs |
|
2021-12-15 |
4 |
OE |
$1.89 |
$336,395 |
D/D |
28,751 |
29,195 |
|
- |
|
Combs Andrew |
EVP, Head of Chemistry |
|
2021-12-14 |
4 |
B |
$11.60 |
$46,400 |
D/D |
4,000 |
268,380 |
2.74 |
- |
|
Combs Andrew |
EVP, Head of Chemistry |
|
2021-12-13 |
4 |
B |
$12.12 |
$48,480 |
D/D |
4,000 |
264,380 |
2.74 |
- |
|
100 Records found
|
|
Page 1 of 4 |
|
|